Country Profiles

Download Full Guide


China offers a wide range of Incentives for Innovation and R&D. The R&D superdeduction has
been renewed and even improved for manufacturing companies. In addition, TASC (Technologically
Advanced Service Companies) and HNTE (High and New Technology Enterprises) statuses offer
reduced taxation amongst other bonuses.

Download Full Guide


China Manufacturing

175% R&D superdeduction 200% R&D superdeduction
Benefit Overview

With a standard 25% corporate income tax rate, the extra 75% superdeduction allows a 18,75% standard generosity. Considering the extra 100% superdeduction, the benefit results in a 25% average generosity.
Eligible Claim Period

Expenses incurred during fiscal year are claimed with the Corporate Income Tax sheet within five months after year end. The scheme is a superdeduction that reduces tax liability, with a 5 to 10 years of carry forward.
Historical Background

Available since many years, the scheme has recently experienced a renewal until at least 2023, in addition to an increase in generosity for all companies and especially manufacturing companies.
Ease of Application

The scheme is based on expenses and investments incurred in the fiscal year, but requires a high level of tracking R&D expenses. Claim is submitted upfront for approval.
Regulating Body Policies

The claims can be assessed from both financial and technical / scientific aspects, at both local and regional levels, so discussions can be engaged in case of disagreements.
Tax authorities have a 20% target for controlling claims.
Eligible Costs

Salaries and social costs for R&D employees (incl. Health, unemployment, pension, maternity costs)
Materials, fuel and power, prototypes and trial models (incl. maintenance, samples adjustment, testing, repair)
Depreciation allowances of R&D equipment including intangible assets – software, patent rights
Design costs for new products
Certificate cost for R&D result.
Issues to Consider

The formalism for demonstrating R&D is very demanding. It is hence very difficult to claim on an opportunistic approach, all R&D and Innovation being labelled upfront.